Brief: Cognition Therapeutics Advancing Zervimesine (Ct1812) For Dementia With Lewy Bodies (DLB) Psychosis
02/03/2026 12:36
March 2 (Reuters) - Cognition Therapeutics Inc CGTX.O: COGNITION THERAPEUTICS ADVANCING ZERVIMESINE (CT1812) FOR DEMENTIA WITH LEWY BODIES (DLB) PSYCHOSIS COGNITION - TO MEET FDA DIVISION OF PSYCHIATRY TO DISCUSS A DLB PSYCHOSIS PROGRAM BY MIDYEAR 2026 Source text: ID:nGNX4vZzFt Further company coverage: CGTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB